Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
03
2019
revised:
14
05
2019
accepted:
12
06
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
30
7
2019
Statut:
epublish
Résumé
Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.
Identifiants
pubmed: 31354820
doi: 10.1155/2019/5692317
pmc: PMC6637676
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
5692317Références
Biochem Pharmacol. 2000 May 15;59(10):1227-36
pubmed: 10736423
Gastric Cancer. 2009;12(4):206-11
pubmed: 20047125
Gastric Cancer. 2013 Oct;16(4):581-9
pubmed: 23266882
Cancer Res Treat. 2012 Dec;44(4):235-41
pubmed: 23341787
J Clin Oncol. 2013 Sep 10;31(26):3219-25
pubmed: 23918952
J Clin Oncol. 2013 Nov 1;31(31):3935-43
pubmed: 24043745
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
Oncol Rep. 2014 Dec;32(6):2319-26
pubmed: 25230742
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
J Clin Oncol. 2016 May 1;34(13):1448-54
pubmed: 26884585
J Clin Oncol. 2016 Aug 10;34(23):2728-35
pubmed: 27325864
Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):887-92
pubmed: 27376400
Cancer Chemother Pharmacol. 2016 Oct;78(4):809-14
pubmed: 27566700
Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064
pubmed: 28850174
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
ESMO Open. 2017 Jul 19;2(3):e000206
pubmed: 29209523
Oncotarget. 2017 Sep 19;8(61):104552-104559
pubmed: 29262660
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
Ann Oncol. 2018 Oct 1;29(10):2052-2060
pubmed: 30052729
J Clin Oncol. 2018 Oct 1;36(28):2836-2844
pubmed: 30110194
Lancet Oncol. 2018 Nov;19(11):1437-1448
pubmed: 30355453
Gastric Cancer. 2019 Mar;22(2):344-354
pubmed: 30506519
Eur J Cancer. 2019 Jan;107:115-123
pubmed: 30557792